[1] Suzuki J.Cerebrovascular “moyamoya” disease[J].Arch Neurol,1969,20(3):288. [2] Hirano Y,Miyawaki S,Imai H,et al.Differences in clinical features among different onset patterns in moyamoya disease[J].J Clin Med,2021,10(13):2815. [3] Sun Y,Zhou G,Feng J,et al.Incidence and prevalence of moyamoya disease in urban China: a nationwide retrospective cohort study[J].Stroke Vasc Neurol,2021,6(4):615~623. [4] 烟雾病和烟雾综合征诊断与治疗中国专家共识编写组,国家卫生计生委脑卒中防治专家委员会缺血性卒中外科专业委员会.烟雾病和烟雾综合征诊断与治疗中国专家共识(2017)[J].中华神经外科杂志,2017(6):541~547. [5] 李建军,赵水平.中国血脂管理指南修订联合专家委员会,中国血脂管理指南(2023年)[J].中国循环杂志,2023,9(3):237~271. [6] 中国高血压防治指南修订委员会,高血压联盟(中国,中华医学会心血管病学分会中国医师协会高血压专业委员会),等.中国高血压防治指南(2018年修订版)[J].中国心血管杂志,2019,24(1):24~56. [7] 中华人民共和国国家卫生和计划生育委员会.成人体重判定:WS/T 428~2013[S].2013. [8] 佚名.中国居民营养与慢性病状况报告:2020年[M].人民卫生出版社,2021. [9] Ge PC,Zhang Q,Ye X,et al.Modifiable risk factors associated with moyamoya disease: A case-control study[J].Stroke,2020,51(8):2472~2479. [10] 张明,王翠兰,刘书东,等.缺血性脑卒中患者再发卒中的危险因素分析[J].山东医药,2016,56(13):83~84. [11] 谢坤,李勇.高甘油三酯血症临床管理多学科专家共识[J].中国循环杂志,2023,38(6):621~633. [12] 鲁远君,文治成,贺传沙.初发与复发缺血性脑卒中患者血清甘油三酯水平对比及其临床意义[J].中国老年学杂志,2012,32(10):2153~2154. [13] Su MW,Chang CK,Lin CW,et al.Blood multiomics reveal insights into population clusters with low prevalence of diabetes,dyslipidemia and hypertension[J].PLoS One,2020,15(3):e0229922. [14] Singh IM,Shishehbor MH,Ansell BJ.High-density lipoprotein as a therapeutic target: a systematic review[J].JAMA,2007,298(7):786~798. [15] 徐建可,刘宁,韩苗,等.缺血性脑卒中患者颈动脉斑块性质与非高密度脂蛋白胆固醇浓度的相关性[J].首都医科大学学报,2023,44(1):49~53. [16] Mertens R,Graupera M,Gerhardt H,et al.The genetic basis of moyamoya disease[J].Transl Stroke Res,2022,13(1):25~45. [17] Dei Cas M,Carrozzini T,Pollaci G,et al.Plasma lipid profiling contributes to untangle the complexity of moyamoya arteriopathy[J].Int J Mol Sci,2021,22(24):13410. [18] Casares D,Escribá PV,Rosselló CA.Membrane lipid composition: effect on membrane and organelle structure,function and compartmentalization and therapeutic avenues[J].Int J Mol Sci.2019,20(9):2167. [19] Ahel J,Lehner A,Vogel A,et al.Moyamoya disease factor RNF213 is a giant E3 ligase with a dynein-like core and a distinct ubiquitin-transfer mechanism[J].Elife,2020,9:e56185. [20] Bersano A,Guey S,Bedini G,et al.Research Progresses in Understanding the Pathophysiology of Moyamoya Disease[J].Cerebrovasc Dis.2016,41(3-4):105~118. [21] 张琦豪.高脂血症患者饮食和运动情况调查[J].河南预防医学杂志,2020,31(4):285~287. [22] 张建红.营养干预对高脂血症肥胖患者血脂水平的影响[J].中国初级卫生保健,2020,34(6):55~56. |